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Abstract
Acute pulmonary embolism (PE) can diminish patient quality of life (QoL). The objective was to 
test whether treatment with tenecteplase has an independent effect on a measurement that reflects 
QoL in patients with submassive PE. This was a secondary analysis of an 8-center, prospective 
randomized controlled trial, utilizing multivariate regression to control for predefined predictors of 
worsened QoL including: age, active malignancy, history of PE or deep venous thrombosis 
(DVT), recurrent PE or DVT, chronic obstructive pulmonary disease and heart failure. QoL was 
measured with the physical component summary (PCS) of the SF-36. Analysis included 76 
patients (37 randomized to tenecteplase, 39 to placebo). Multivariate regression yielded an 
equation f(8, 67), P<0.001, with R2 = 0.303. Obesity had the largest effect on PCS (β = −8.6, 
P<0.001), with tenecteplase second (β = 4.73, P = 0.056). After controlling for all interactions, 
tenecteplase increased the PCS by +5.37 points (P = 0.027). In patients without any of the defined 
comorbidities, the coefficient on the tenecteplase variable was not significant (−0.835, P = 0.777). 
In patients with submassive PE, obesity had the greatest influence on QoL, followed by use of 
fibrinolysis. Fibrinolysis had a marginal independent effect on patient QoL after controlling for 
comorbidities, but was not significant in patients without comorbid conditions.
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Introduction
The effect of acute pulmonary embolism (PE) on patient quality of life (QoL) has been 
previously studied using both the generic Short Form 36 (SF-36) instrument as well as the 
more disease-specific pulmonary embolism quality of life (PEmb-QoL) instrument [1, 2]. 
Klok et al. found that survivors of acute PE have significantly lower QoL scores than age- 
and sex-adjusted population norms [2]. They also found that age, obesity (BMI>30 kg/m2), 
active malignancy and cardiopulmonary comorbidities were associated with worsened QoL 
after acute PE [2]. However, patient QoL after acute PE remains significantly understudied. 
Despite the existing knowledge of the negative impact of acute PE on patient QoL 
outcomes, much debate still remains concerning the treatment of PE, specifically in the use 
of fibrinolytics in acute submassive PE.
The recent TOPCOAT study demonstrated an increased probability of a good functional 
composite outcome in patients with submassive PE randomized to treatment with 
tenecteplase. TOPCOAT used the normalized score on the SF-36 physical component 
summary (PCS) score as one measurement of the composite functional outcome and 
identified a score less than two standard deviations below the mean as a poor outcome [3]. 
However, this trial was terminated early with the resultant possibility for imbalanced 
randomization and associated bias [4]. The objective of this work was to investigate the 
effect of fibrinolysis on the PCS score measured in patients with acute submassive PE, using 
a multivariate linear regression analysis to control for other predictors of poor QoL.
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Materials and methods
Overall design
This was a secondary analysis of a multicenter, prospective trial with enrollment occurring 
at eight academic emergency departments [3]. Inclusion criteria for the original study were 
as follows: (i) age>17 years; (ii) PE diagnosed on CTPA performed within 24 h; and (iii) 
normal arterial systolic blood pressure with evidence of RV strain. Exclusion criteria 
included systolic hypotension (SBP<90 mmHg), inability to walk, contraindications to 
fibrinolysis, and end-stage conditions. A more detailed methodology of this study has been 
previously illustrated in a separate publication [5]. This study was approved at each of the 
Institutional Review boards of participating hospitals and all patients gave written informed 
consent. This trial was registered NCT00680628.
Quality of life
Patient QoL was measured at follow-up at 90 days using a normalized PCS score, which 
incorporates scores from the physical function, role physical, bodily pain and general health 
subscales of the SF-36 [6]. This method of measuring QoL was chosen during the initial 
planning phase of the original study in 2008. At that time, disease-specific instruments for 
assessing QoL, such as the PEmb-QoL, had not yet been developed and validated. 
Therefore, the more generic SF-36 instrument was selected, as it is a tool that has been 
extensively utilized in clinical research. This survey was administered by trained researchers 
to patients at a follow-up appointment 90 days from diagnosis of PE.
Statistical analysis
Using methods similar to those described previously, we constructed a multivariate linear 
regression to test the independent predictive value of treatment with tenecteplase on the 
outcome variable of PCS score [7]. Predefined independent predictor variables, derived from 
Klok et al., included in the regression equation were: age (transformed by loge), obesity 
(defined as BMI>30 kg/m2), active malignancy (defined as ongoing care by an oncologist, 
palliative treatment or metastatic disease), history of PE or DVT, recurrent PE or DVT, 
chronic obstructive pulmonary disease and congestive heart failure. These predictor 
variables, identified through patient report, represented specific demographics and comorbid 
conditions that we expected to influence patient QoL measures based on previously 
published studies [2]. The primary study question was the marginal contribution of 
tenecteplase to the PCS score after controlling for all other variables in an average marginal 
effects model. As a secondary analysis to document magnitude of independent contribution 
of tenecteplase, we did not set an a priori P value to reject the null hypothesis. 
Heteroskedasticity-consistent standard errors were calculated to account for non-normality 
due to small sample size. Statistical analyses were performed using StataSE 13 (College 
Station, TX).
Results
The original study included 40 patients in the tenecteplase group and 43 in the placebo 
group. Of these 83 patients, a total of seven patients (three from tenecteplase and four from 
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placebo) were omitted from this analysis as they either died during initial hospitalization (n 
= 1 treated with placebo and n = 1 treated with tenecteplase) or were lost to follow-up (n = 2 
tenecteplase and n = 3 placebo) and were therefore unavailable to complete the SF-36. The 
clinical characteristics of study participants are shown in Table 1. This table contains 
demographic data as well as the specific comorbid conditions included in the multivariate 
regression equation. Patients in the group randomized to tenecteplase had an average age of 
56 (SD of 13, median age = 57). This group had an average BMI of 32.5 kg/m2 (median = 
30.4 kg/m2) with 54 % defined as obese with a BMI>30 kg/m2. The placebo group 
contained patients with an average age of 54 (SD of 15, median age = 52) and mean BMI of 
34.2 kg/m2 (median = 33.6 kg/m2) with 64 % with a BMI over 30 kg/m2. The comorbid 
conditions listed in Table 1 include active malignancy, chronic obstructive pulmonary 
disease and systolic heart failure. Five patients (14 %) randomized to tenecteplase were 
reported to have an active malignancy by the explicit definition, compared to zero 
randomized to placebo. Three placebo patients had COPD (8 %) compared to zero 
tenecteplase patients. One patient (3 %) in each treatment group had systolic heart failure. 
Table 1 also includes data on prior history of PE or DVT [five (14 %) of tenecteplase and 
eight (21 %) of placebo] and recurrent PE or DVT [one (3 %) of tenecteplase and four (10 
%) of placebo].
The main outcome investigated in this secondary analysis was the PCS score from the 
SF-36. The mean PCS score reported from patients randomized to the tenecteplase group 
was 46.8 (SD 10) compared to 41.6 (SD 13) in the placebo group (between group difference 
of 5.2 points). Table 2 shows the results from the regression analysis. Multivariate 
regression with PCS score as the dependent variable yielded an equation F(8,67), P<0.001 
with an estimated R2 value of 0.3026, indicating that ~30 % of the variance in the PCS score 
was explained by the eight predictors. Obesity was found to have the largest effect on PCS 
score (coefficient of −8.6, P ≤ 0.001), indicating that obese patients with a BMI over 30 
kg/m2 scored an average of 8.6 points lower on the PCS than their non-obese counterparts. 
Fibrinolysis had the second most important effect on PCS score. The tenecteplase variable 
had a coefficient of 4.73 with borderline statistical significance (P = 0.056), thus suggesting 
that the use of tenecteplase versus placebo in patients with acute submassive PE was 
associated with increased patient QoL at 90 days as measured by the PCS score on the 
SF-36. After transformation with the natural logarithm, the coefficient for age was 7.61 (P = 
0.083), indicating that for approximately every 10 % increase in patient age, the PCS score 
decreased by 7.6 points.
Data were collected for all possible interactions to investigate the effect of tenecteplase 
when under the influence of each potential combination of comorbid conditions. Table 3 
lists the results of the interaction between tenecteplase and the independent predictor 
variables included in the regression. We could not test for interaction between tenecteplase 
and malignancy as all patients with active malignancy were randomized to tenecteplase. 
Similarly, the interaction between tenecteplase and COPD was not assessed as all patients 
with COPD were randomized to placebo. The interaction with recurrent PE or DVT was 
found to be significant (coefficient of 16.06, P = 0.018). This indicates that the increase in 
PCS score associated with tenecteplase was 16.06 points greater in patients with recurrent 
PE or DVT than in patients without recurrent thromboembolism. The interaction with heart 
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failure was also significant (coefficient of 33.31, P =<0.001), although this result may be 
unreliable as there was only one heart failure patient in each group. Utilizing an average 
marginal effects model based on the data gathered from the regression including interaction 
terms, we were able to determine the effect of tenecteplase after controlling for the effect of 
all other predictor variables on the tenecteplase coefficient. The coefficient for tenecteplase 
after controlling for interactions was determined to be 5.37 with P = 0.027, providing further 
indication of the independent effect of tenecteplase on the PCS score. Because the standard 
deviation of the normalized PCS score is about ten points, this suggests that a +5.37 point 
increase equates to approximately a 33 % improvement in patient perception of physical 
wellness afforded by tenecteplase relative to those receiving placebo [6]. An additional 
notable finding from the regression plus interactions was the effect of tenecteplase in 
patients without comorbidities. The coefficient of the tenecteplase variable in patients with 
no comorbidities was not significant (−0.835, P = 0.777), suggesting no effect of fibrinolysis 
on QoL in otherwise healthy patients with PE.
Table 4 shows the enrollment features of the patients excluded from analysis because of 
death in the initial hospitalization period or loss to follow-up. This table was included to 
investigate whether there existed any imbalance in the predictors utilized in the regression 
analysis. Seven patients (three in tenecteplase group and four in placebo group) were 
omitted from this analysis. One patient in each treatment group died. The average age of 
those omitted from the tenecteplase group was 71 (SD 16) and in the placebo group was 54 
(SD 7). The average BMI from those omitted from tenecteplase was 34.1 kg/m2 (SD 12.6) 
compared to 31.7 kg/m2 (SD 5.5) for placebo. One patient in the tenecteplase group had a 
history of PE/DVT. One patient in the placebo group had a history of systolic heart failure. 
No patients were omitted from either group with an active malignancy or history of COPD.
Discussion
This study evaluated the relative quantitative contribution of treatment with tenecteplase 
(fibrinolysis) to a measurement of QoL after acute submassive PE. Obesity had the largest 
negative independent effect on QoL, reducing the PCS by 8.6 points, when assessed 90 days 
later. Fibrinolysis was associated with a 5.4-point increase in normalized PCS score and had 
its greatest positive effect in patients with prior VTE or heart failure. Our findings support 
previous reports that survivors of acute PE have diminished QoL, and their QoL is further 
decreased by comorbid conditions. Specifically, work conducted by Klok et al. on a 
population of 392 patients with a history of acute PE found that these patients had 
significantly lower QoL on seven subscales of the SF-36 as compared to sex- and age-
adjusted Dutch population norms [2]. These differences were most pronounced in the 
subscales associated with physical role limitation and functioning. A more recent study by J. 
van Es et al. also demonstrated decreased QoL in survivors of PE, utilizing both the SF-36 
as well as the more disease specific PEmb-QOL instrument [1]. To our knowledge, ours is 
the first study to measure the independent effect of fibrinolytics on patient QoL measures 
after adjusting for comorbid conditions. Although no data on QoL or long- term follow up 
were provided in the recently published PEITHO study, the largest randomized controlled 
trial of thrombolytics in submassive PE to ever be conducted, analysis of functional status 
and severity of dyspnea after 180 days is planned [8, 9]. These data should provide 
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additional information on the effect of thrombolytics on QoL and may provide insight on 
which patients are most likely to benefit from thrombolytic therapy.
The independent predictor variables we chose to include in our regression analysis were 
based on previously published data identifying specific clinical characteristics including 
obesity, active malignancy, prior PE and cardiopulmonary comorbid conditions, to be 
significant predictors of impaired QoL [2]. Results from the multivariate regression equation 
shown in Table 2 provide additional support for this hypothesis, demonstrating obesity to be 
a significant independent predictor of reduced PCS scores, having the overall greatest effect 
of all regression variables on the SF-36, even more so than the use of fibrinolysis. The 
significant negative effect of obesity on PCS score was not a particularly surprising finding, 
as obesity has been extensively studied and shown to result in diminished patient QoL 
across all conditions [10]. However, we were surprised to find the impact of obesity on PCS 
score to be greater than the impact of treatment with fibrinolysis. Another somewhat 
surprising finding in the data obtained from our regression plus interactions analysis was 
that in otherwise healthy patients with none of the comorbid conditions included as our 
potential confounders, fibrinolysis showed no benefit on patient QoL. However, this finding 
can be interpreted as consistent with findings from Klok et al., who found comorbid 
conditions to cause a major decrement in SF-36 scores in patients with PE [2]. Taken 
together, these findings generally suggest that fibrinolysis in submassive PE has its greatest 
effect on preventing deterioration in patients likely to have their QoL decreased by PE in 
association with comorbid conditions, such as recurrent VTE or coexisting heart failure.
This study reports an important novel finding with patient-oriented treatment implications, 
as it is the first to demonstrate an independent effect on fibrinolysis on a QoL measure in 
patients with submassive PE. PE has been associated with reduced right ventricular function, 
persistent dyspnea and lower exercise tolerance [11, 12]. Patients desire to avoid these 
outcomes. Using the standard gamble technique, Hogg et al. studied perceptions of patients 
with prior DVT or PE to scripted negative consequences of DVT, PE, gastrointestinal or 
intracranial hemorrhage [13]. The PE script included a description of persistent dyspnea. 
These patients rated the PE script worse than the DVT script and similar to gastrointestinal 
hemorrhage or minor intracranial hemorrhage script, but less severe than the major 
intracranial hemorrhage script [13]. Treatment of acute submassive PE with fibrinolysis is a 
controversial topic in current clinical practice, as clinicians seek to balance the potential 
benefit of adjunctive fibrinolysis on short-term hemodynamic stability versus risk of major 
hemorrhage with the long-term health outcomes of severe PE treated with anticoagulation 
only [14]. The results of this study could be employed by practicing clinicians as an 
additional piece of evidence when advising patients as to the risks and benefits of therapy.
It is important to note additional limitations of this study. The results do not show a robust 
effect of tenecteplase, with P = 0.056 in the base equation, suggesting more than 5 % 
probability that tenecteplase did not have a significant, independent effect on PCS score. 
Further, seven patients from the original TOPCOAT trial had to be omitted from this 
secondary analysis. One patient randomized to each group died during the initial 
hospitalization, thus balancing their exclusion to some degree. However, an additional five 
patients were lost to follow-up and unable to fill out SF-36 surveys. The clinical 
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characteristics of these patients were investigated to determine whether a significant 
imbalance existed between those initially randomized to separate treatment groups. These 
enrollment features are shown in Table 4. Another possible limitation of this study was the 
relatively small sample size. The small number of patients in each group resulted in low 
numbers of patients with comorbid conditions. This limited our overall data analysis, 
specifically the examination of interaction effects, as we were unable to interact tenecteplase 
with malignancy and COPD. The smaller sample size may also explain why clinical 
characteristics described in previous publications to be significant determinants of decreased 
QoL, such as malignancy, prior history of PE or DVT, and cardiopulmonary comorbidities, 
were not reported to be significant in our results, as this study may have been underpowered 
to detect such effects. It should also be mentioned that no consensus exists currently as to 
the most accurate instrument for measuring patient QoL after PE. The SF-36 was chosen in 
the initial study based on its extensive history of use and the lack of a disease-specific 
instrument at that time.
Conclusion
In patients with acute submassive PE, obesity had the greatest effect on PCS score of the 
SF-36. Fibrinolysis had the second largest contribution, as a single bolus of tenecteplase was 
found to independently increase the PCS score at 90-day follow-up after adjusting for eight 
comorbid conditions. Examination of interactions revealed that tenecteplase did not increase 
the PCS score in patients who lacked the pre-specified comorbid conditions.
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Table 2
Multivariate regression analysis results
Variables Estimated coefficients for physical component summary score P
Tenecteplase 4.73 0.056
Age (natural logarithm) −7.60 0.083
Obesity (BMI>30 kg/m2) −8.59 <0.001
Active malignancy −8.26 0.178
History of PE or DVT −0.30 0.924
Recurrent PE or DVT −8.95 0.072
Chronic obstructive pulmonary disease −5.32 0.329
Heart Failure −12.61 0.143
PE pulmonary embolism, DVT deep venous thrombosis, BMI body mass index
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Table 3
Interaction results
Interaction term with tenecteplase Estimated coefficients P
Age (natural logarithm) −11.29 0.185
Obesity (BMI>30 kg/m2) 5.43 0.238
History PE or DVT 6.20 0.276
Recurrent PE or DVT 16.06 0.018
Heart failure 33.31 <0.001
PE pulmonary embolism, DVT deep venous thrombosis, BMI body mass index
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Table 4
Clinical characteristics of patients omitted from original trial
Clinical finding Placebo Tenecteplase
N =4 N= 3
Obese (BMI>30 kg/m2) 3 75 % 1 33 %
Active malignancy 0 0 % 0 0 %
Prior history of PE or DVT 0 0 % 1 33 %
Chronic obstructive pulmonary disease 0 0 % 0 0 %
Heart failure 1 25 % 0 0 %
Age (years, mean and SD) 54 (7) 71 (16)
Body mass index (kg/m2) 32 (6) 34 (13)
PE pulmonary embolism, DVT deep venous thrombosis, BMI body mass index, SD standard deviation
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